版本:
中国

BRIEF-VBL Therapeutics announces fourth quarter 2016 financial results

March 27 Vascular Biogenics Ltd

* VBL Therapeutics announces fourth quarter and year end 2016 financial results

* Vascular Biogenics Ltd - at Dec 31, 2016, co had cash, cash equivalents and short-term bank deposits of $45.3 million and working capital of $41.8 million

* Vascular Biogenics- expects cash, cash equivalents,short-term bank deposits to fund operating expenses,capital expenditure requirements into 2019

* Vascular Biogenics Ltd - intends to operate and relocate to new site in Israel in second half of 2017

* Vascular Biogenics Ltd - "Intend to launch a phase 3 pivotal study in platinum-resistant ovarian cancer during second half of 2017" Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐